GlassScriptPhysician profile
Summer Causey Buchhamer
NPI 1952942997
$2,646.14
in general payments reported to CMS, 2019-2025
19 companies · $538 in 2025
The $538 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $209 · 2022: $330 · 2023: $785 · 2024: $784 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $844.76 | 2022-2024 | Xarelto |
| Abiomed | $591.97 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $228.57 | 2021-2023 | Farxiga |
| Amgen INC. | $219.94 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $133.02 | 2022-2024 | |
| Boston Scientific Corporation | $95.84 | 2025 | Watchman Flx, Jetstream Sc |
| Inspire Medical Systems, INC. | $92.76 | 2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.00 | 2023 | Lifevest |
| Merck Sharp & Dohme LLC | $76.35 | 2023-2024 | Verquvo |
| Novo Nordisk INC | $55.21 | 2021-2025 | Wegovy |
| Pfizer INC. | $44.60 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.41 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $33.72 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.96 | 2022 | |
| Amarin Pharma, INC. | $20.16 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $18.52 | 2024 | Uptravi, Opsumit |
| Lexicon Pharmaceuticals, INC. | $17.24 | 2023 | Inpefa |
| Glaxosmithkline, LLC. | $16.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Buchhamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.